MMP9 and colitis: The prevention of intestinal mucosal barrier injury observed in pioglitazone-treated mice with colitis was also associated with increased expressions of tight junction proteins and reduced protein levels of TNF-α, IL-6, and MMP9, which are soluble mediators controlled by the ERK-NF-κB [38].